found that in epithelial ovarian cancer patients receiving immune checkpoint inhibitor therapy, increased serum MUC16 levels correlated with poor immunotherapy outcomes, suggesting its prognostic indicator value (89). This evidence concerns the gene MUC16 and ovarian carcinoma.